Prescribing Update Newsletter – May 2022

Prescribing support newsletters aim to inform readers of work done by the unit and work in progress, to help tailor local work plans and highlight any ‘topical’ issues in prescribing or medicines management.

If you have any suggestions for future topics for the newsletter, then please contact nuth.nyrdtc.rxsupp@nhs.net

This month’s edition covers the RDTC’s Climate Emergency declaration, Pill Swallowing – a skill for life, Metolazone preparations and safety considerations, and the second in the series of “Meet the Team” where you can get to know the people behind the work we do. We also cover the Price concessions and the Discount Deduction scheme, World Antimicrobial Awareness Week, and a guide to the COVID-19 autumn booster. There is also information on the changes to the Medicines Information Service, and some key medicines availability issues.

This month’s edition covers how the RDTC can support stakeholder organisations, our recent publications, and the prescribing support workplan. It also has features on post exposure prophylaxis for chickenpox and shingles, the national flu immunisation programme 2022-23, inadvertent oral administration of potassium permanganate, the CVD eLearning programme, WHO changes to the treatment of drug-resistant tuberculosis, and sources of information on menopause and HRT availability.

Brolucizumab for wet age-related macular degeneration

Overview

New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs.

Brolucizumab is a monoclonal antibody specific for vascular endothelial growth factor (VEGF). It is indicated for treatment of wet age-related macular degeneration (AMD), and is administered as an intravitreal injection every eight or 12 weeks.

Download the full review below to read more.

NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid until the 31st of December 2023.
For more information visit www.nice.org/accreditation